ARCHIVES

Afinitor Increases Overall Survival To 3.5 Years in Phase III Trial

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

DCCR Merit Review Of Contracts Finds Most Perform Satisfactorily; 21 Phased Out Early

January 5, 1979

New Concept For Prevention Units Goes to DCPC BSC

April 24, 1987

Without Advisor’s Input, Healy Approves Protocol For Gene Therapy

January 15, 1993

In Brief: NCI Awards $1.2 Million To Mt. Sinai To Establish Specialized Cancer Center

July 26, 1974

Biotheraputices To Reveal Plans for Expansion

August 8, 1986

Brown Needs Decision By March 31; Sander Decline HEW Offer

March 4, 1977